```html

Yellow‑green Bacterial Conjunctivitis

Overview

Yellow‑green bacterial conjunctivitis is an acute infection of the conjunctiva (the thin, transparent membrane that lines the inner surface of the eyelids and covers the white part of the eye) caused primarily by gram‑negative bacteria that produce a characteristic yellow‑green discharge. The most common pathogens are Haemophilus influenzae, Moraxella catarrhalis, and, less frequently, Pseudomonas aeruginosa or Staphylococcus aureus that produce a pigmented exudate.

The condition is highly contagious and can affect anyone, but it is most prevalent in:

• Children ages 5–12 years (especially in daycare or school settings)
• Adults who work in close‑contact environments (health‑care workers, teachers, military personnel)
• People with chronic eye irritation, contact‑lens wear, or pre‑existing ocular surface disease

According to the Centers for Disease Control and Prevention (CDC), bacterial conjunctivitis accounts for roughly 30–50 % of all infectious conjunctivitis cases in the United States, and the “yellow‑green” subtype represents about 10 % of bacterial cases, translating to an estimated 1–2 million new episodes each year worldwide【1】.

Symptoms

Symptoms typically appear 1–3 days after exposure to the bacteria and may affect one or both eyes. The hallmark is the thick, yellow‑green purulent discharge that can cause the eyelids to stick together, especially upon waking. Other common findings include:

• Redness (hyperemia): diffuse or localized to the palpebral conjunctiva.
• Itching or irritation: a gritty or burning sensation.
• Swelling of the eyelids (edema) and periorbital skin.
• Excess tearing (epiphora) due to irritation.
• Light sensitivity (photophobia): mild to moderate.
• Blurred vision: usually temporary and improves after clearing the discharge.
• Foreign‑body sensation: feeling of something in the eye.
• Fever or upper‑respiratory symptoms: may accompany the infection, especially in children.

Unlike viral conjunctivitis, the discharge is thick and colored rather than watery, and the onset is often more abrupt.

Causes and Risk Factors

Primary causative organisms

• Haemophilus influenzae (most common in children)
• Moraxella catarrhalis (often follows upper‑respiratory infection)
• Pseudomonas aeruginosa (particularly in contact‑lens wearers)
• Staphylococcus aureus (including MRSA strains)

Transmission

• Direct hand‑to‑eye contact after touching contaminated secretions.
• Sharing towels, washcloths, eye makeup, or contact‑lens solutions.
• Aerosolized droplets from coughing or sneezing in close quarters.

Risk factors that increase susceptibility

• Age < 12 years (immature immune response)
• Contact‑lens wear, especially extended‑wear lenses without proper hygiene
• Recent upper‑respiratory infection or sinusitis
• Allergic eye disease that compromises the ocular surface
• Immunosuppression (HIV, chemotherapy, systemic steroids)
• Exposure to crowded settings (daycare, military barracks, nursing homes)

Diagnosis

Diagnosis is primarily clinical, based on history and physical examination. Physicians look for the characteristic yellow‑green purulent discharge and conjunctival injection.

Clinical Evaluation

1. History: onset, exposure to infected contacts, contact‑lens habits, recent upper‑respiratory infection.
2. Visual acuity test: to rule out more serious corneal involvement.
3. Slit‑lamp examination: assesses conjunctival membranes, corneal clarity, and presence of follicles or pus.

Laboratory Tests (when needed)

• Conjunctival swab for Gram stain & culture: indicated if the infection is severe, recurrent, or there is suspicion of atypical organisms (e.g., Pseudomonas or MRSA). Results usually return in 48–72 hours.
• Polymerase‑chain reaction (PCR): increasingly used for rapid identification of bacterial DNA, especially in outbreak settings.
• Antibiotic susceptibility testing: guides therapy if the organism is resistant to first‑line agents.

In most uncomplicated cases, laboratory testing is not required, and empirical therapy is started based on typical presentation.

Treatment Options

The goal of treatment is to eradicate the pathogen, relieve symptoms, and prevent transmission. Because the infection is bacterial, antibiotics are the mainstay.

First‑line Antibiotics

• Topical fluoroquinolones (e.g., ciprofloxacin 0.3 % drops, ofloxacin 0.3 % drops) – effective against gram‑negative organisms and widely available.
• Topical macrolides (e.g., azithromycin 1 % ophthalmic solution) – convenient once‑daily dosing, good for mild‑moderate cases.
• Topical sulfonamides (e.g., trimethoprim‑polymyxin B) – useful when fluoroquinolone resistance is a concern.

Typical duration: **5–7 days**. Most patients experience marked improvement within 48–72 hours.

Second‑line / Alternative Therapies

• Oral antibiotics: indicated for severe keratitis, orbital cellulitis, or if the organism is known to be resistant (e.g., oral amoxicillin‑clavulanate for Haemophilus).
• Contact‑lens removal: immediately discontinue lens wear; disinfect lenses or replace with a new pair after the infection resolves.
• Adjunctive measures: warm compresses 4–6 times daily to loosen crusting; lubricating (preservative‑free) artificial tears to reduce irritation.

Supportive Care

• Frequent hand washing with soap and water.
• Avoid rubbing the eyes.
• Discard any eye makeup or solutions used in the 24 hours before symptom onset.
• Use separate towels for each family member.

Living with Yellow‑green Bacterial Conjunctivitis

While the infection is self‑limiting with treatment, daily life may be impacted. Below are practical tips:

• Maintain a clean environment: Change pillowcases daily; disinfect bathroom surfaces with a bleach‑based cleaner.
• Protect your vision: Wear sunglasses outdoors to reduce photophobia.
• Stay home from school or work: until 24 hours after starting antibiotics and the discharge has markedly decreased, per CDC guidance.
• Manage discomfort: Over‑the‑counter acetaminophen or ibuprofen can alleviate mild pain and fever.
• Monitor symptoms: Keep a brief diary of discharge color, vision changes, and pain level to share with your clinician.

Prevention

Because contagion is a key feature, prevention focuses on hygiene and minimizing exposure.

1. Hand hygiene: Wash hands with soap for at least 20 seconds before touching eyes, after blowing your nose, and after using the bathroom.
2. Contact‑lens care: Follow the manufacturer’s cleaning regimen, replace lenses as recommended, and avoid sleeping in lenses not approved for overnight wear.
3. Avoid sharing personal items: Towels, washcloths, cosmetics, eye drops, or pillowcases.
4. Environmental cleaning: Regularly disinfect surfaces in high‑traffic areas (doorknobs, light switches, shared computers).
5. Vaccination: The Hib (Haemophilus influenzae type b) vaccine reduces carriage of H. influenzae, indirectly lowering the risk of conjunctivitis in children.
6. Prompt treatment of upper‑respiratory infections: Reduce bacterial load that can seed the conjunctiva.

Complications

When left untreated or when inappropriate therapy is used, several complications may arise:

• Corneal ulceration: Bacterial invasion of the cornea can lead to pain, scarring, and permanent visual impairment.
• Phlyctenular keratoconjunctivitis: An immune‑mediated response that may cause nodular lesions on the conjunctiva.
• Secondary bacterial keratitis: Especially common in contact‑lens wearers; requires aggressive treatment.
• Orbital cellulitis: Rare but serious spread of infection to orbital tissues, presenting with swelling, pain, and fever.
• Chronic conjunctivitis: Persistent redness and discharge lasting >4 weeks, often due to inadequate treatment or resistant organisms.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Conjunctivitis (pink eye). Updated 2023. https://www.mayoclinic.org
2. CDC. Conjunctivitis – Bacterial. 2022. https://www.cdc.gov
3. American Academy of Ophthalmology. Conjunctivitis. 2021. https://www.aao.org
4. NIH National Eye Institute. Eye infections. 2023. https://nei.nih.gov
5. Cleveland Clinic. Yellow‑green conjunctivitis. 2022. https://my.clevelandclinic.org
6. World Health Organization. Vaccines against Haemophilus influenzae type b. 2021. https://www.who.int

```